FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3169833232> ?p ?o ?g. }

• W3169833232 endingPage "101" @default.
• W3169833232 startingPage "93" @default.
• W3169833232 abstract "Ataxia Telangiectasia Mutated (ATM) serine/threonine protein kinase is a known tumor suppressor, involved in DNA damage repair. It has prognostic and predictive therapeutic implications and is associated with aggressive prostate cancer (PCa).To investigate the prognostic value of ATM protein expression in PCa patients and assessed the combined value of ATM, ERG, and PTEN status.This study consisted of 303 patients with incidental, locally advanced, and castrate-resistant PCa by transurethral resection of the prostate (TURP).TURP samples from 303 PCa patients were assessed by immunohistochemistry (IHC for ATM, ERG, and PTEN. Individual and combined marker status were correlated with International Society of Urological Pathology Gleason grade group, overall survival (OS), and PCa-specific mortality (PCSM).Decreased ATM expression (negative/weak intensity) occurred in 164/303 (54.1%) patients, and was associated with shorter OS and higher PCSM (p = 0.015 and p = 0.001, respectively). Negative/weak ATM expression was significantly associated with PCSM with a hazard ratio of 2.09 (95% confidence interval 1.34-3.27, p = 0.001). Assessment of Combined ATM/PTEN expression showed improved prognostic power to predict OS and PCSM, independent of Gleason grade groups.Decreased ATM protein expression is associated with poor outcomes in advanced PCa patients. Patients with combined low ATM/PTEN negative expression are at the highest risk for reduced OS and PCSM. Assessing the combined status of ATM/PTEN by IHC in PCa patients may aid in risk stratification relative to OS and PCSM. Moreover, since ATM plays an integral role in DNA damage response pathways, future studies will enhance our understanding of how outcomes of patients with altered ATM and PTEN expression can be improved further with poly-ADP ribose polymerase inhibitors (PARPi), combinations of PARPi and androgen receptor-targeted therapies, as well as platinum-based chemotherapies.Lower ATM intensity is associated with increased cancer-specific mortality in prostate cancer patients. Patients with lower ATM and PTEN negative expression showed decreased overall survival and increased cancer mortality compared with controls." @default.
• W3169833232 created "2021-06-22" @default.
• W3169833232 creator A5007657275 @default.
• W3169833232 creator A5012063931 @default.
• W3169833232 creator A5023028363 @default.
• W3169833232 creator A5024462443 @default.
• W3169833232 creator A5035453779 @default.
• W3169833232 creator A5042167871 @default.
• W3169833232 creator A5043414341 @default.
• W3169833232 creator A5061507303 @default.
• W3169833232 creator A5069016257 @default.
• W3169833232 date "2021-07-01" @default.
• W3169833232 modified "2023-09-26" @default.
• W3169833232 title "Decreased ATM Protein Expression Is Substantiated with PTEN Loss in Defining Aggressive Phenotype of Prostate Cancer Associated with Lethal Disease" @default.
• W3169833232 cites W2058606238 @default.
• W3169833232 cites W2098128741 @default.
• W3169833232 cites W2141265794 @default.
• W3169833232 cites W2159972811 @default.
• W3169833232 cites W2169599916 @default.
• W3169833232 cites W2237583211 @default.
• W3169833232 cites W2315322086 @default.
• W3169833232 cites W2414367793 @default.
• W3169833232 cites W2462985846 @default.
• W3169833232 cites W2806267204 @default.
• W3169833232 cites W2887867165 @default.
• W3169833232 cites W2895362009 @default.
• W3169833232 cites W2898571963 @default.
• W3169833232 cites W2922433043 @default.
• W3169833232 cites W2957456724 @default.
• W3169833232 cites W2972107575 @default.
• W3169833232 cites W2989894179 @default.
• W3169833232 cites W2997243361 @default.
• W3169833232 cites W3011487857 @default.
• W3169833232 cites W3015673613 @default.
• W3169833232 cites W3087416729 @default.
• W3169833232 cites W3096768659 @default.
• W3169833232 doi "https://doi.org/10.1016/j.euros.2021.05.004" @default.
• W3169833232 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8317877" @default.
• W3169833232 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34337539" @default.
• W3169833232 hasPublicationYear "2021" @default.
• W3169833232 type Work @default.
• W3169833232 sameAs 3169833232 @default.
• W3169833232 citedByCount "4" @default.
• W3169833232 countsByYear W31698332322022 @default.
• W3169833232 countsByYear W31698332322023 @default.
• W3169833232 crossrefType "journal-article" @default.
• W3169833232 hasAuthorship W3169833232A5007657275 @default.
• W3169833232 hasAuthorship W3169833232A5012063931 @default.
• W3169833232 hasAuthorship W3169833232A5023028363 @default.
• W3169833232 hasAuthorship W3169833232A5024462443 @default.
• W3169833232 hasAuthorship W3169833232A5035453779 @default.
• W3169833232 hasAuthorship W3169833232A5042167871 @default.
• W3169833232 hasAuthorship W3169833232A5043414341 @default.
• W3169833232 hasAuthorship W3169833232A5061507303 @default.
• W3169833232 hasAuthorship W3169833232A5069016257 @default.
• W3169833232 hasBestOaLocation W31698332321 @default.
• W3169833232 hasConcept C121608353 @default.
• W3169833232 hasConcept C126322002 @default.
• W3169833232 hasConcept C143998085 @default.
• W3169833232 hasConcept C190283241 @default.
• W3169833232 hasConcept C204232928 @default.
• W3169833232 hasConcept C207103383 @default.
• W3169833232 hasConcept C2776235491 @default.
• W3169833232 hasConcept C2777609662 @default.
• W3169833232 hasConcept C2780192828 @default.
• W3169833232 hasConcept C44249647 @default.
• W3169833232 hasConcept C502942594 @default.
• W3169833232 hasConcept C55493867 @default.
• W3169833232 hasConcept C71924100 @default.
• W3169833232 hasConcept C86554907 @default.
• W3169833232 hasConcept C86803240 @default.
• W3169833232 hasConceptScore W3169833232C121608353 @default.
• W3169833232 hasConceptScore W3169833232C126322002 @default.
• W3169833232 hasConceptScore W3169833232C143998085 @default.
• W3169833232 hasConceptScore W3169833232C190283241 @default.
• W3169833232 hasConceptScore W3169833232C204232928 @default.
• W3169833232 hasConceptScore W3169833232C207103383 @default.
• W3169833232 hasConceptScore W3169833232C2776235491 @default.
• W3169833232 hasConceptScore W3169833232C2777609662 @default.
• W3169833232 hasConceptScore W3169833232C2780192828 @default.
• W3169833232 hasConceptScore W3169833232C44249647 @default.
• W3169833232 hasConceptScore W3169833232C502942594 @default.
• W3169833232 hasConceptScore W3169833232C55493867 @default.
• W3169833232 hasConceptScore W3169833232C71924100 @default.
• W3169833232 hasConceptScore W3169833232C86554907 @default.
• W3169833232 hasConceptScore W3169833232C86803240 @default.
• W3169833232 hasFunder F4320306163 @default.
• W3169833232 hasFunder F4320319921 @default.
• W3169833232 hasLocation W31698332321 @default.
• W3169833232 hasLocation W31698332322 @default.
• W3169833232 hasLocation W31698332323 @default.
• W3169833232 hasLocation W31698332324 @default.
• W3169833232 hasOpenAccess W3169833232 @default.
• W3169833232 hasPrimaryLocation W31698332321 @default.
• W3169833232 hasRelatedWork W1602913332 @default.
• W3169833232 hasRelatedWork W2142008762 @default.
• W3169833232 hasRelatedWork W2169228223 @default.
• W3169833232 hasRelatedWork W2312375518 @default.

• next